|

MB-CART19.1 Clinical Trials

2 actively recruiting trials

Also known as: Anti-CD19 CAR T cells, CD19-targeting CAR T cells

Pipeline

Phase 1/2: 1

Top Sponsors

  • Miltenyi Biomedicine GmbH2

Indications

  • SLE - Systemic Lupus Erythematosus1
  • Chronic Lymphatic Leukemia1
  • Childhood Non-Hodgkin Lymphoma1
  • Acute Lymphatic Leukemia1
  • Melanoma Stage III1

Other2 trials

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
N/A
MB-CART19.1 in Refractory SLE
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.